These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Caution issued against use of morcellators. Motluk A CMAJ; 2015 Feb; 187(2):99. PubMed ID: 25534604 [No Abstract] [Full Text] [Related]
24. What is the Future of Open Intraperitoneal Power-Morcellation of Fibroids? Parker WH; Pritts EA; Olive DL Clin Obstet Gynecol; 2016 Mar; 59(1):73-84. PubMed ID: 26670834 [TBL] [Abstract][Full Text] [Related]
25. Highmark leads on procedure but other plans slow to follow. Diamond F Manag Care; 2014 Sep; 23(9):54. PubMed ID: 25282868 [No Abstract] [Full Text] [Related]
26. The Essential Elements of a Robotic-Assisted Laparoscopic Hysterectomy. Simpson KM; Advincula AP Obstet Gynecol Clin North Am; 2016 Sep; 43(3):479-93. PubMed ID: 27521880 [TBL] [Abstract][Full Text] [Related]
27. Complications in Laparoscopic Supracervical Hysterectomy(LASH), especially the morcellation related. Krentel H; De Wilde RL Best Pract Res Clin Obstet Gynaecol; 2016 Aug; 35():44-50. PubMed ID: 26694587 [TBL] [Abstract][Full Text] [Related]
28. Iatrogenic parasitic leiomyoma and leiomyomatosis peritonealis disseminata following uterine morcellation. Lu B; Xu J; Pan Z J Obstet Gynaecol Res; 2016 Aug; 42(8):990-9. PubMed ID: 27125448 [TBL] [Abstract][Full Text] [Related]
29. An unusual complication of suture material after robotic assisted myomectomy. Simsek T J Obstet Gynaecol; 2012 Oct; 32(7):708. PubMed ID: 22943731 [No Abstract] [Full Text] [Related]
30. Total laparoscopic hysterectomy without uterine manipulator: description of a new technique and its outcome. Kavallaris A; Chalvatzas N; Kelling K; Bohlmann MK; Diedrich K; Hornemann A Arch Gynecol Obstet; 2011 May; 283(5):1053-7. PubMed ID: 20449598 [TBL] [Abstract][Full Text] [Related]
32. Dermatology-related postmarketing study commitments to the Food and Drug Administration. Bognet RA; Chiang DS; Katz KA J Am Acad Dermatol; 2006 Oct; 55(4):721-3. PubMed ID: 17010760 [No Abstract] [Full Text] [Related]
33. Representativeness in Premarketing vs Postmarketing US Food and Drug Administration Trials. Unger JM JAMA Netw Open; 2021 Apr; 4(4):e217159. PubMed ID: 33877312 [No Abstract] [Full Text] [Related]
34. Removal of pelvic leiomyomata and endometriosis five years after supracervical hysterectomy. Hilger WS; Magrina JF Obstet Gynecol; 2006 Sep; 108(3 Pt 2):772-4. PubMed ID: 17018497 [TBL] [Abstract][Full Text] [Related]
35. Surgical removal of multiple mesenteric fibroids (Kg 4,500) by abdominal spread of previous laparoscopic uterine myomectomy. Leanza V; Gulino FA; Leanza G; Zarbo G G Chir; 2015; 36(1):32-5. PubMed ID: 25827668 [TBL] [Abstract][Full Text] [Related]
36. The Food and Drug Administration Amendments Act and postmarketing commitments. Fain K; Daubresse M; Alexander GC JAMA; 2013 Jul; 310(2):202-4. PubMed ID: 23839755 [No Abstract] [Full Text] [Related]
38. A primer on postmarketing surveillance. Drug Inf J; 1987; 21(1):67-107. PubMed ID: 10281639 [No Abstract] [Full Text] [Related]
39. Morcellation and myomas: Balancing decisions around minimally invasive treatments for fibroids. Siedhoff MT; Kim KH J Surg Oncol; 2015 Dec; 112(7):769-71. PubMed ID: 26768314 [TBL] [Abstract][Full Text] [Related]
40. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]